<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972617</url>
  </required_header>
  <id_info>
    <org_study_id>Albumin - Furosemid</org_study_id>
    <nct_id>NCT04972617</nct_id>
  </id_info>
  <brief_title>Characterization of the Efficacy of Furosemide Depending on Albumin Function</brief_title>
  <official_title>Characterization of the Efficacy of Furosemide Depending on Albumin Function - a Prospective Monocentric Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During this prospective, uncontrolled and non-interventional observational study, the&#xD;
      influence of albumin function on the efficacy of furosemide will be investigated. The aim of&#xD;
      the study is to provide information on the efficacy of furosemide depending on albumin&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with intravenous furosemide administration, an additional 15 ml of blood is taken&#xD;
      for the analysis of specific parameters as part of the blood sampling necessary for the&#xD;
      treatment of the patient.&#xD;
&#xD;
      The effect of furosemide is assessed on the basis of the patient's urine excretion. For this&#xD;
      purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at&#xD;
      the beginning of the balancing period.&#xD;
&#xD;
      In addition, the albumin concentration, ABiC, as well as the total and free concentration of&#xD;
      furosemide in the collected urine are determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the ratio of urine output to fluid input after initiation of furosemide therapy in correlation to the ABiC</measure>
    <time_frame>6 hours post-dose</time_frame>
    <description>Assessment of the ABiC 5 minutes after furosemid administration as well as urine output and fluid input for 6 hours post-dose for every hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the levels of the patient-specific unbound furosemide fraction in correlation to the ABiC</measure>
    <time_frame>5 minutes post-dose</time_frame>
    <description>Assessment of the patient-specific unbound furosemide fraction 5 minutes after furosemid administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of disease severity on ABiC</measure>
    <time_frame>12 hours</time_frame>
    <description>Correlation of clinical parameters of critical ill patients with the ABiC:&#xD;
Comorbidities of the organ subsystems (cardio-pulmonary, abdominal, nephrological, endocrinological)&#xD;
Drug intake&#xD;
Conditions affecting critically ill patients (haemodynamic status, sepsis, ARDS, nutritional status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of biochemical parameters on ABiC</measure>
    <time_frame>12 hours</time_frame>
    <description>Correlation of biochemical parameters of critical ill patients with the ABiC:&#xD;
Hemogram&#xD;
Acid-base balance&#xD;
Organ-specific parameters (kidney, liver, immune system)&#xD;
Albumin&#xD;
Unbound forusemide fraction&#xD;
Urine analysis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Renal Failure</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>observational group</arm_group_label>
    <description>In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.&#xD;
The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.&#xD;
In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>albumin function analysis (ABIC)</intervention_name>
    <description>After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80Â° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.</description>
    <arm_group_label>observational group</arm_group_label>
    <other_name>analysis of total furosemide concentration</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        intensive care patients admitted to University Hospital Rostock&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Attending intensive care physician intends to prescribe IV furosemide to increase&#xD;
             urine output&#xD;
&#xD;
          -  Arterial (central venous if applicable) and urinary catheter in situ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Attending intensive care physician intends to prescribe further doses of diuretic&#xD;
             medication (including furosemide infusion) within the 6 hours required for fluid&#xD;
             collection&#xD;
&#xD;
          -  Patients who received intravenous or oral diuretics (including mannitol) in the 6&#xD;
             hours prior to study enrolment&#xD;
&#xD;
          -  Patients who have received other medications (e.g. fludrocortisone) known to affect&#xD;
             renal sodium or water excretion in the 24 hours prior to study entry&#xD;
&#xD;
          -  Patients with uncontrolled hyperglycaemia (plasma glucose &gt;10mmol/L).&#xD;
&#xD;
          -  Patients who were receiving renal replacement therapy prior to the start of the study&#xD;
&#xD;
          -  Patients with obstructive uropathy, macroscopic haematuria or intra-abdominal&#xD;
             hypertension (&gt;20mmHg)&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Mitzner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerd Klinkmann, MD</last_name>
    <phone>+49 381 494 6494</phone>
    <email>gerd.klinkmann@med.uni-rostock</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerd Klinkmann, Dr. med.</last_name>
      <phone>+49 381 494 6494</phone>
      <email>gerd.klinkmann@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Gerd Klinkmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steffen Mitzner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Gerd Klinkmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>furosemide</keyword>
  <keyword>albumin function</keyword>
  <keyword>albumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

